Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy (vol 50, pg 955, 2015)

Zhou Jun; Peng Zhi; Liu Yi; Gong Jifang; Zhang Xiaotian; Lu Ming; Gao Jing; Li Yili; Li Yanyan; Shen Lin

首页> 外文期刊>Journal of gastroenterology >Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy (vol 50, pg 955, 2015)

【24h】

Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy (vol 50, pg 955, 2015)

机译：曲妥珠单抗联合化疗治疗HER2阳性晚期胃癌患者血清HER2 ECD的预测价值（第50卷，第955页，2015年）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of gastroenterology》 |2016年第5期|共2页
作者
Zhou Jun; Peng Zhi; Liu Yi; Gong Jifang; Zhang Xiaotian; Lu Ming; Gao Jing; Li Yili; Li Yanyan; Shen Lin;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy (vol 50, pg 955, 2015) [J] . Zhou Jun, Peng Zhi, Liu Yi, Journal of gastroenterology . 2016,第5期

机译：曲妥珠单抗联合化疗治疗HER2阳性晚期胃癌患者血清HER2 ECD的预测价值（第50卷，第955页，2015年）
2. Comment: Gomez-Martin et al. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol 2013. (18) [J] . International Journal of Radiation Oncology, Biology, Physics . 2014,第4期

机译：评论：Gomez-Martin等。 HER2基因扩增水平可预测曲妥珠单抗治疗的HER2阳性晚期胃癌的应答和总生存期。 J临床肿瘤学2013.（18）
3. Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab [J] . Carlos Gomez-Martin, Jose Carlos Plaza, Roberto Pazo-Cid, Journal of Clinical Oncology . 2013,第35期

机译：HER2基因扩增水平预测曲妥珠单抗治疗的HER2阳性晚期胃癌的应答和总生存率
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated anthracycline-naïve HER2-positive locally advanced/metastatic breast cancer [O] . Kathy Miller, Javier Cortes, Sara A. Hurvitz, 2016

机译：HERMIONE：MM-302联合曲妥珠单抗与医师选择的化学疗法加曲妥珠单抗在之前治疗过无蒽环类HER2阳性局部晚期/转移性乳腺癌的患者中进行的随机2期试验
7. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer [O] . 2016

机译：HERMIONE：MM-302加曲妥珠单抗与医师选择的化疗加曲妥珠单抗的2期随机对照试验，用于先前已治疗，无蒽环类，HER2阳性，局部晚期/转移性乳腺癌的患者

Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy (vol 50, pg 955, 2015)

著录项

相似文献

相关主题

期刊订阅